Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SQM013
MIFTS: 76

Squamous Cell Carcinoma, Head and Neck

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases, Endocrine diseases, Oral diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

About this section

MalaCards integrated aliases for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 57 13
Squamous Cell Carcinoma of the Head and Neck 38 12 53 25 75 29 6 73
Hnscc 57 53 25 59 75 55
Head and Neck Squamous Cell Carcinoma 12 53 25 59 15
Carcinoma, Squamous Cell of Head and Neck 76 53 44
Head and Neck Cancer 53 43
Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinuses 59
Squamous Cell Carcinoma of the Nasal Cavity and Sinuses 59
Squamous Cell Carcinoma, Head and Neck, Somatic 57
Squamous Cell Carcinoma of the Hypopharynx 59
Squamous Cell Carcinoma of Salivary Glands 59
Squamous Cell Carcinoma of the Oral Cavity 59
Squamous Cell Carcinomas of Head and Neck 12
Squamous Cell Carcinoma of the Oropharynx 59
Squamous Cell Carcinoma of Head and Neck 59
Carcinoma, Squamous Cell, Head and Neck 40
Squamous Cell Carcinoma of the Larynx 59
Squamous Cell Carcinoma of the Lip 59
Carcinoma of the Head and Neck 12
Squamous Cell Carcinoma of Lip 73
Lip Squamous Cell Carcinoma 55
Neoplasm of Head and Neck 6
Cancer of Head and Neck 73
Scchn 25

Characteristics:

Orphanet epidemiological data:

59
squamous cell carcinoma of head and neck
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases Oral diseases
See all MalaCards categories (disease lists)
Orphanet: 59  
Rare gastroenterological diseases


Sources

Summaries for Squamous Cell Carcinoma, Head and Neck

About this section
MedlinePlus : 43 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to thyroid cancer and squamous cell carcinoma, and has symptoms including coughing, halitosis and snoring. An important gene associated with Squamous Cell Carcinoma, Head and Neck is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Phospholipase-C Pathway and PI3K-Akt signaling pathway. The drugs Erbitux and Ethyol have been mentioned in the context of this disorder. Affiliated tissues include skin, salivary gland and lung, and related phenotypes are squamous cell carcinoma and Decreased cell migration

UniProtKB/Swiss-Prot : 75 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

NIH Rare Diseases : 53 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments.

Genetics Home Reference : 25 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Wikipedia : 76 Squamous cell carcinomas, also known as epidermoid carcinoma are a number of different types of cancer... more...

Description from OMIM: 275355
Sources

Related Diseases for Squamous Cell Carcinoma, Head and Neck

About this section

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Related Disease Score Top Affiliating Genes
1 thyroid cancer 34.2 BRAF H19 HOTAIR HRAS PIK3CA PTEN
2 squamous cell carcinoma 33.1 BRAF FGFR3 H19 HOTAIR HRAS ING1
3 breast cancer 11.7 BRAF CYTOR EPB41L4A-DT H19 HOTAIR HRAS
4 colorectal cancer 11.7 BRAF CYTOR FGFR3 H19 HOTAIR HRAS
5 lung cancer 11.7 BRAF EPB41L4A-DT H19 HOTAIR HRAS MIR205
6 glioblastoma 11.7 BRAF CYTOR H19 HOTAIR HRAS IDH2
7 gastric adenocarcinoma 11.7 BRAF H19 HOTAIR HRAS MAP2K2 PIK3CA
8 glioma 11.7 BRAF CYTOR H19 HOTAIR IDH2 MIR21
9 adenocarcinoma 11.7 BRAF FGFR3 H19 HRAS PIK3CA PTEN
10 cervical cancer 11.7 FGFR3 H19 HOTAIR HRAS MIR21 PIK3CA
11 hepatocellular carcinoma 11.7 CYTOR H19 HOTAIR HRAS IDH2 MIR205
12 esophageal cancer 11.7 CYTOR H19 HOTAIR HRAS MIR205 MIR21
13 cholangiocarcinoma 11.7 H19 HRAS IDH2 MIR21 PIK3CA PTEN
14 suppression of tumorigenicity 12 11.6 BRAF HRAS PIK3CA PTEN SMAD4 TP53
15 lung cancer susceptibility 3 11.6 BRAF CYTOR FGFR3 H19 HOTAIR HRAS
16 adamantinoma of long bones 11.6 BRAF CYTOR H19 HOTAIR PIK3CA PTEN
17 renal cell carcinoma, papillary, 1 11.6 BRAF FGFR3 HRAS PIK3CA PTEN TP53
18 gastrointestinal system cancer 11.6 H19 HOTAIR HRAS PIK3CA PTEN SMAD4
19 ovarian cancer 11.6 BRAF H19 HOTAIR MIR21 MIR210 PIK3CA
20 pancreatic cancer 11.6 CYTOR H19 HOTAIR HRAS MIR205 MIR21
21 lung squamous cell carcinoma 11.6 BRAF FGFR3 HRAS PIK3CA PTEN TP53
22 prostate cancer 11.6 H19 HOTAIR HRAS MIR205 MIR21 MIR210
23 brain cancer 11.6 BRAF HRAS IDH2 PIK3CA PTEN TP53
24 bladder squamous cell carcinoma 11.6 BRAF FGFR3 PIK3CA PTEN TP53
25 myeloma, multiple 11.6 BRAF FGFR3 H19 HOTAIR HRAS IDH2
26 bladder urothelial carcinoma 11.6 BRAF FGFR3 HOTAIR HRAS PIK3CA TP53
27 pilocytic astrocytoma 11.6 BRAF HRAS PIK3CA PTEN TP53
28 gastric cancer 11.6 CYTOR H19 HOTAIR MIR21 PIK3CA PTEN
29 skin melanoma 11.6 BRAF HRAS PIK3CA PTEN TP53
30 pancreas adenocarcinoma 11.6 HRAS MAP2K2 PIK3CA SMAD4 TP53
31 endometrial cancer 11.6 BRAF H19 HOTAIR HRAS PIK3CA PTEN
32 esophagus adenocarcinoma 11.6 MIR21 PIK3CA SMAD4 TP53
33 brain stem glioma 11.6 BRAF IDH2 PIK3CA TP53
34 melanoma 11.6 BRAF H19 HOTAIR MIR205 MIR210 PTEN
35 skin squamous cell carcinoma 11.6 BRAF HRAS PIK3CA TP53
36 giant cell glioblastoma 11.6 BRAF FGFR3 PTEN TP53
37 anaplastic thyroid cancer 11.6 BRAF PIK3CA PTEN TP53
38 small cell cancer of the lung 11.6 HOTAIR MIR21 PIK3CA PTEN TP53
39 bladder cancer 11.6 FGFR3 H19 HOTAIR HRAS MIR205 MIR21
40 female reproductive organ cancer 11.6 HRAS PIK3CA PTEN TP53
41 oral cavity cancer 11.6 PIK3CA PTEN TNFRSF10B TP53
42 ovarian serous cystadenocarcinoma 11.6 BRAF HRAS PIK3CA TP53
43 leukemia, acute myeloid 11.6 HOTAIR HRAS IDH2 MIR21 MIR210 TP53
44 respiratory system cancer 11.6 HRAS PIK3CA PTEN TP53
45 testicular germ cell tumor 11.6 BRAF FGFR3 PTEN TP53
46 kidney cancer 11.6 EPB41L4A-DT H19 HOTAIR MIR21 MIR210
47 gallbladder cancer 11.6 CYTOR H19 HOTAIR PIK3CA TP53
48 uterine carcinosarcoma 11.6 HRAS PIK3CA PTEN TP53
49 medulloblastoma 11.6 H19 HOTAIR PIK3CA PTEN TNFRSF10B TP53
50 glioblastoma multiforme 11.6 MIR21 MIR210 PIK3CA PTEN TP53

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck
Sources

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

About this section

Symptoms via clinical synopsis from OMIM:

57
Lab:
beta family transforming growth factor resistance


Clinical features from OMIM:

275355

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

32
# Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 32 HP:0002860

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


coughing, halitosis, snoring, tinnitus, sore throat, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.55 BRAF FGFR3 HRAS MAP2K2 PIK3CA
2 Decreased viability in esophageal squamous lineage GR00235-A 9.32 BRAF FGFR3 HRAS IDH2 ING1 PIK3CA
3 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 PTEN SMAD4

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 SMAD4 TP53 BRAF FGFR3 HRAS MAP2K2
2 integument MP:0010771 9.56 TP53 BRAF FGFR3 HRAS MAP2K2 PIK3CA
3 neoplasm MP:0002006 9.32 TP53 BRAF FGFR3 HRAS IDH2 ING1
Sources

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Ethyol 18 AMIFOSTINE Alza December 8, 1995
3
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 270)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
3
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
4 Alkylating Agents Phase 4,Phase 2,Phase 1,Not Applicable
5 Mitomycins Phase 4,Phase 2,Not Applicable
6 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
11 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
12 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
15
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 84093 441203 2767
16
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
17
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
18
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
19
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124
20
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
21
nivolumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
22
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
23
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
24
Zinc Approved, Investigational Phase 3,Phase 2,Phase 1 7440-66-6 23994
25
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
26
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
27
Indomethacin Approved, Investigational Phase 3,Phase 2,Phase 1 53-86-1 3715
28
Vinblastine Approved Phase 3 865-21-4 13342 241903
29
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
31
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
32 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
33
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
34
Tremelimumab Investigational Phase 3,Phase 1,Phase 2 745013-59-6
35 Nimorazole Investigational Phase 3,Phase 2 6506-37-2
36 Endostatins Phase 3,Phase 2 71581480
37
s 1 (combination) Phase 3
38 Respiratory System Agents Phase 3,Phase 2
39 Adrenergic Agents Phase 3,Phase 2
40 Adrenergic Agonists Phase 3,Phase 2
41 Adrenergic alpha-Agonists Phase 3,Phase 2
42 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
43 Adrenergic beta-Agonists Phase 3,Phase 2
44 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
45 Mydriatics Phase 3,Phase 2
46 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
47 Anesthetics Phase 3
48 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
49 Dermatologic Agents Phase 3,Phase 2,Phase 1
50 Angiogenesis Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 509)
# Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
3 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
4 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
5 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
6 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
7 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
8 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
9 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
10 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
11 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
12 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3 Erlotinib chlorhydrate;Cisplatin
13 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
14 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Completed NCT00206219 Phase 3 Gefitinib;methotrexate
15 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
16 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed NCT01177956 Phase 3 Cisplatin;5-Fluorouracil
17 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
18 Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial Completed NCT00995293 Phase 3 DOCETAXEL;CISPLATIN;5-FLUOROURACIL
19 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Completed NCT00122460 Phase 3 Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
20 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Completed NCT00496652 Phase 3 Zalutumumab
21 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00460265 Phase 3 ARM 2;ARM 1
22 Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT00401323 Phase 2, Phase 3 docetaxel (XRP6976);cisplatin;5-fluorouracil (5-FU)
23 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
24 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
25 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
26 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
27 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
28 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
29 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed NCT00424255 Phase 3 Lapatinib
30 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
31 Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer Completed NCT00273546 Phase 3 XRP6976 (Docetaxel/Taxotere)
32 Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer Completed NCT03370367 Phase 3 13-cis retinoic acid
33 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Completed NCT01265849 Phase 3
34 Changes in Body Composition After EPA Supplementation in Head and Neck Patients Recruiting NCT02715596 Phase 3
35 A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03452137 Phase 3 Atezolizumab;Placebo
36 Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Recruiting NCT02952586 Phase 3 Avelumab
37 Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck Recruiting NCT01427478 Phase 3 AFATINIB;Placebo of AFATINIB
38 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Recruiting NCT03349710 Phase 3 Placebo;Cisplatin
39 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02741570 Phase 3 Cetuximab/Erbitux;Cisplatin/Platinol;Carboplatin/Paraplatin;Fluorouracil/Adrucil
40 Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial Recruiting NCT02765503 Phase 3
41 Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) Recruiting NCT02999087 Phase 3 Cetuximab;avelumab;Cisplatin
42 DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Recruiting NCT03237325 Phase 3 SGX942;Placebo
43 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Recruiting NCT02661152 Phase 3 Nimorazole
44 Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer Recruiting NCT01772706 Phase 3
45 Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Recruiting NCT02236936 Phase 3 Cisplatin
46 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Active, not recruiting NCT02105636 Phase 3 Nivolumab;Cetuximab;Methotrexate;Docetaxel
47 Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
48 Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Active, not recruiting NCT00999700 Phase 3 docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin
49 Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Subjects With Head and Neck Cancer Active, not recruiting NCT02383966 Phase 3 Cetuximab;Cisplatin/Carboplatin;5-fluorouracil
50 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Active, not recruiting NCT02551159 Phase 3 5-fluorouracil (5FU);Cisplatin;Carboplatin

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Cochrane evidence based reviews: carcinoma, squamous cell of head and neck

Sources

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

About this section

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 29 ING1 PTEN TNFRSF10B
Sources

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

About this section

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

41
Skin, Salivary Gland, Lung, Lymph Node, Testes, Prostate, Endothelial
Sources

Publications for Squamous Cell Carcinoma, Head and Neck

About this section

Articles related to Squamous Cell Carcinoma, Head and Neck:

(show top 50) (show all 911)
# Title Authors Year
1
Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck. ( 29022097 )
2018
2
High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy. ( 29345108 )
2018
3
Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion. ( 29360262 )
2018
4
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. ( 28950305 )
2017
5
Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. ( 28622889 )
2017
6
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017. ( 29250200 )
2017
7
p16 expression in cutaneous squamous cell carcinoma of the head and neck is not associated with integration of high risk HPV DNA or prognosis. ( 28663082 )
2017
8
MiR-98 inhibits malignant progression via targeting MTDH in squamous cell carcinoma of the head and neck. ( 29312808 )
2017
9
GTSP1 expression in non-smoker and non-drinker patients with squamous cell carcinoma of the head and neck. ( 28817620 )
2017
10
Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck. ( 28755705 )
2017
11
Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. ( 28602169 )
2017
12
Mild pulmonary emphysema a risk factor for interstitial lung disease when using cetuximab for squamous cell carcinoma of the head and neck. ( 28741444 )
2017
13
Chapter 3 The Role of PET/CT in Squamous Cell Carcinoma of the Head and Neck. ( 29031365 )
2017
14
Basaloid Squamous Cell Carcinoma of the Head and Neck: Subclassification into Basal, Ductal, and Mixed Subtypes Based on Comparison of Clinico-pathologic Features and Expression of p53, Cyclin D1, Epidermal Growth Factor Receptor, p16, and Human Papillomavirus. ( 28593937 )
2017
15
Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. ( 28199044 )
2017
16
Expression of the extracellular sulfatase SULF2 is associated with squamous cell carcinoma of the head and neck. ( 27223083 )
2016
17
Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. ( 26858129 )
2016
18
Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab. ( 28125819 )
2016
19
Positive frozen section margins predict local recurrence in R0-resected squamous cell carcinoma of the head and neck. ( 27016013 )
2016
20
The role of autophagy in squamous cell carcinoma of the head and neck. ( 26774913 )
2016
21
A Limited Immunohistochemical Panel to Distinguish Basal Cell Carcinoma of Cutaneous Origin From Basaloid Squamous Cell Carcinoma of the Head and Neck. ( 27438511 )
2016
22
Influence of Photodynamic Therapy on the Expression of Cancer/Testis Antigens in Squamous Cell Carcinoma of the Head and Neck. ( 27466502 )
2016
23
A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. ( 26711789 )
2016
24
Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. ( 27683114 )
2016
25
Tumor Biomarkers in Spindle Cell Variant Squamous Cell Carcinoma of the Head and Neck. ( 26980915 )
2016
26
Relative expression of vascular endothelial growth factor isoforms in squamous cell carcinoma of the head and neck. ( 25521093 )
2016
27
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. ( 26712222 )
2016
28
Downregulation of EGFR in hypoxic, diffusion-limited areas of squamous cell carcinomas of the head and neck. ( 27802455 )
2016
29
Variants of EVER1 and EVER2 (TMC6 and TMC8) and human papillomavirus status in patients with mucosal squamous cell carcinoma of the head and neck. ( 27097911 )
2016
30
Current surgical management of metastases in the neck from mucosal squamous cell carcinoma of the head and neck. ( 26432197 )
2016
31
Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment. ( 27322955 )
2016
32
WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. ( 27285764 )
2016
33
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. ( 25876000 )
2015
34
A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. ( 25680594 )
2015
35
Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck. ( 25868613 )
2015
36
Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. ( 26483987 )
2015
37
Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. ( 26028524 )
2015
38
Metadherin regulation of vascular endothelial growth factor expression is dependent upon the PI3K/Akt pathway in squamous cell carcinoma of the head and neck. ( 25674742 )
2015
39
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. ( 25639864 )
2015
40
DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. ( 26001739 )
2015
41
Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. ( 25670542 )
2015
42
Nano-Quadrapeutics rapidly detects and destroys squamous cell carcinoma of the head and neck. ( 25677387 )
2015
43
Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. ( 25810697 )
2015
44
Wilms' tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck. ( 25929687 )
2015
45
HPV-related squamous cell carcinoma of the head and neck: An update on testing in routine pathology practice. ( 25724476 )
2015
46
The role of Pyk2 in the CCR7-mediated regulation of metastasis and viability in squamous cell carcinoma of the head and neck cells in vivo and in vitro. ( 26352169 )
2015
47
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. ( 25333206 )
2015
48
Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). ( 25725588 )
2015
49
Systemic therapy for squamous cell carcinoma of the head and neck. ( 25979393 )
2015
50
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. ( 25892145 )
2015
Sources

Variations for Squamous Cell Carcinoma, Head and Neck

About this section

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

75
# Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6
(show top 50) (show all 673)
# Gene Variation Type Significance SNP ID Assembly Location
1 TNFRSF10B TNFRSF10B, 2-BP INS insertion Pathogenic
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
3 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
4 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh37 Chromosome 10, 89692878: 89692878
5 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh38 Chromosome 10, 87933121: 87933121
6 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh37 Chromosome 13, 111372083: 111372083
7 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh38 Chromosome 13, 110719736: 110719736
8 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh37 Chromosome 13, 111372086: 111372086
9 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh38 Chromosome 13, 110719739: 110719739
10 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh37 Chromosome 13, 111372014: 111372014
11 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh38 Chromosome 13, 110719667: 110719667
12 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
13 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh38 Chromosome 19, 4117553: 4117553
14 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
15 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
16 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
17 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
18 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
19 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
20 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
21 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
22 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
23 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
24 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
25 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
26 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
27 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
28 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
29 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
30 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
31 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
32 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
33 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
34 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
35 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
36 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
37 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
38 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
39 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
40 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
41 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
42 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
43 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
44 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
45 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
46 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
47 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
48 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
49 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
50 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9
(show top 50) (show all 2260)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10662 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 90
2 COSM607136 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 90
3 COSM6962965 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 90
4 COSM6962990 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 90
5 COSM6962984 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 90
6 COSM6962994 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 90
7 COSM6962992 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 90
8 COSM6962970 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 90
9 COSM456125 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 90
10 COSM1700914 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 90
11 COSM6962989 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 90
12 COSM6962963 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.310G>A p.G104R 7:106867871-106867871 90
13 COSM6962964 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.3227G>A p.R1076K 7:106905305-106905305 90
14 COSM564 NRAS skin,neck,carcinoma,squamous cell carcinoma c.35G>A p.G12D 1:114716126-114716126 90
15 COSM6962996 NCOA3 skin,neck,carcinoma,squamous cell carcinoma c.979C>T p.H327Y 20:47634062-47634062 90
16 COSM4170532 MTOR skin,neck,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 1:11212464-11212464 90
17 COSM6962967 KMT2C skin,neck,carcinoma,squamous cell carcinoma c.11659C>T p.H3887Y 7:152158874-152158874 90
18 COSM6962983 KMT2A skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 90
19 COSM498 HRAS skin,neck,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 90
20 COSM6438927 HGF skin,neck,carcinoma,squamous cell carcinoma c.974C>T p.P325L 7:81729671-81729671 90
21 COSM6962960 FGFR3 skin,neck,carcinoma,squamous cell carcinoma c.2421A>G p.*807W 4:1807262-1807262 90
22 COSM6962980 FGFR2 skin,neck,carcinoma,squamous cell carcinoma c.2234C>T p.S745F 10:121483765-121483765 90
23 COSM6962962 EPHA7 skin,neck,carcinoma,squamous cell carcinoma c.2468G>A p.G823E 6:93254711-93254711 90
24 COSM5918388 EPHA5 skin,neck,carcinoma,squamous cell carcinoma c.2608G>A p.E870K 4:65348104-65348104 90
25 COSM6962957 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.632T>A p.M211K 3:89210338-89210338 90
26 COSM6946976 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.533G>A p.G178E 3:89210239-89210239 90
27 COSM6962956 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1382C>T p.T461I 2:201286485-201286485 90
28 COSM3713589 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1093C>T p.L365F 2:201285055-201285055 90
29 COSM21323 ATM skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 90
30 COSM6950941 APC skin,neck,carcinoma,squamous cell carcinoma c.536C>T p.S179F 5:112780794-112780794 90
31 COSM6962953 AKT3 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 90
32 COSM6962993 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 90
33 COSM99602 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 90
34 COSM1640830 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 90
35 COSM6962972 skin,neck,carcinoma,squamous cell carcinoma c.1727G>A p.S576N 9:8504347-8504347 90
36 COSM6962978 skin,neck,carcinoma,squamous cell carcinoma c.2237C>T p.S746F 10:121483765-121483765 90
37 COSM6962995 skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 90
38 COSM1350749 skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 90
39 COSM6962951 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 90
40 COSM1700913 skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 90
41 COSM1700915 skin,neck,carcinoma,squamous cell carcinoma c.1252C>T p.P418S 9:8518130-8518130 90
42 COSM6962982 skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 90
43 COSM6962950 skin,neck,carcinoma,squamous cell carcinoma c.430C>T p.P144S 1:77966737-77966737 90
44 COSM1700912 skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 90
45 COSM6962991 skin,neck,carcinoma,squamous cell carcinoma c.1369C>T p.P457S 17:40356221-40356221 90
46 COSM99020 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 90
47 COSM6962979 skin,neck,carcinoma,squamous cell carcinoma c.1967C>T p.S656F 10:121483765-121483765 90
48 COSM99021 skin,neck,carcinoma,squamous cell carcinoma c.464G>A p.R155Q 17:7674220-7674220 90
49 COSM6962952 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 90
50 COSM6962969 skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 90

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification EVI1 head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MDS1 head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion DLEC head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplific ation EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain FAK head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma
42 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma
Sources

Expression for Squamous Cell Carcinoma, Head and Neck

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane protease, serine 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine-rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T-cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin, beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17, type I Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4, type II Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone-like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1, interferon-inducible Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.
Sources

Pathways for Squamous Cell Carcinoma, Head and Neck

About this section

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Phospholipase-C Pathway 64
Show member pathways
 13.1 BRAF FGFR3 HRAS MAP2K2 PTEN TP53
2
PI3K-Akt signaling pathway 37
Show member pathways
 13.01 FGFR3 HRAS MAP2K2 PIK3CA PTEN TP53
3
Development Angiotensin activation of ERK 22
Show member pathways
 12.96 BRAF HRAS MAP2K2 PIK3CA TNFRSF10B TP53
4
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.89 BRAF FGFR3 HRAS MAP2K2 PIK3CA PTEN
5
Endometrial cancer 37
Show member pathways
 12.88 BRAF HRAS MAP2K2 PIK3CA PTEN SMAD4
6
Apoptosis Modulation and Signaling 1
Show member pathways
 12.84 HRAS MAP2K2 PIK3CA TNFRSF10B TP53
7
MAPK signaling pathway 1 37
12.8 BRAF FGFR3 HRAS MAP2K2 TP53
8
Glioma 37
Show member pathways
 12.77 BRAF FGFR3 HRAS MAP2K2 PIK3CA PTEN
9
Ras signaling pathway 37
Show member pathways
 12.76 BRAF FGFR3 HRAS MAP2K2 PIK3CA
10
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.76 FGFR3 HRAS PIK3CA PTEN TP53
11
Gastric cancer 37
Show member pathways
 12.76 BRAF HRAS MAP2K2 PIK3CA PTEN SMAD4
12
Pathways in cancer 37
12.76 BRAF FGFR3 HRAS MAP2K2 PIK3CA PTEN
13
Development HGF signaling pathway 22
Show member pathways
 12.74 BRAF HRAS MAP2K2 PIK3CA PTEN TP53
14
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.7 HRAS MAP2K2 PIK3CA PTEN TNFRSF10B
15
Regulation of actin cytoskeleton 37 1
12.65 BRAF FGFR3 HRAS MAP2K2 PIK3CA
16
Kaposi's sarcoma-associated herpesvirus infection 37
Show member pathways
 12.6 HRAS MAP2K2 PIK3CA PTEN SMAD4 TP53
17
Development EGFR signaling pathway 22
Show member pathways
 12.56 BRAF HRAS MAP2K2 PIK3CA SMAD4 TP53
18
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.55 BRAF HRAS MAP2K2 PIK3CA TNFRSF10B
19
Prolactin Signaling Pathway 1 37
Show member pathways
 12.5 HRAS MAP2K2 PIK3CA PTEN
20
ErbB signaling pathway 1 37
Show member pathways
 12.5 BRAF HRAS MAP2K2 PIK3CA TP53
21
Development FGFR signaling pathway 22
Show member pathways
 12.46 FGFR3 HRAS MAP2K2 PIK3CA
22
Apoptosis Pathway 72
Show member pathways
 12.46 FGFR3 HRAS MAP2K2 PIK3CA TP53
23
HTLV-I infection 37
12.45 HRAS PIK3CA SMAD4 TP53
24
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.43 BRAF HRAS MAP2K2 PIK3CA
25
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.41 BRAF HRAS MAP2K2 PIK3CA PTEN
26
DNA Damage Response 1
Show member pathways
 12.4 MIR210 PTEN TNFRSF10B TP53
27
B Cell Receptor Signaling Pathway (sino) 67
Show member pathways
 12.36 HRAS MAP2K2 PIK3CA PTEN
28
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.33 BRAF FGFR3 HRAS MAP2K2 PIK3CA PTEN
29
Signaling by FGFR2 66
Show member pathways
 12.3 BRAF FGFR3 HRAS PIK3CA
30
VEGF Signaling Pathway 67 61
Show member pathways
 12.26 FGFR3 HRAS MAP2K2 PTEN
31
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.24 BRAF HRAS MAP2K2 TP53
32
Proteoglycans in cancer 37
12.24 BRAF HRAS MAP2K2 MIR21 PIK3CA TP53
33
Colorectal Cancer Metastasis 64
12.22 BRAF MAP2K2 SMAD4 TP53
34
EGF/EGFR Signaling Pathway 1
12.21 BRAF HRAS MAP2K2 PTEN
35
Kit receptor signaling pathway 1
Show member pathways
 12.2 HRAS MAP2K2 PIK3CA PTEN
36
mTOR Pathway 72
Show member pathways
 12.19 BRAF HRAS MAP2K2 PIK3CA TP53
37
Integrated Breast Cancer Pathway 1
12.18 BRAF PTEN SMAD4 TP53
38
AKT Signaling Pathway 67
12.18 FGFR3 HRAS PIK3CA PTEN TP53
39
Cellular senescence (KEGG) 37
12.18 HRAS MAP2K2 PIK3CA PTEN TP53
40
NGF Pathway 64
Show member pathways
 12.17 BRAF HRAS MAP2K2 TP53
41
Development EGFR signaling via small GTPases 22
Show member pathways
 12.16 HRAS MAP2K2 PIK3CA PTEN
42
Signaling pathways regulating pluripotency of stem cells 37
12.11 FGFR3 HRAS MAP2K2 PIK3CA SMAD4
43
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.1 BRAF FGFR3 MAP2K2
44
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.1 FGFR3 HRAS MAP2K2 PIK3CA SMAD4 TNFRSF10B
45
Hepatitis C 37
12.09 BRAF HRAS PIK3CA TP53
46
Autophagy - animal 37
12.08 HRAS MAP2K2 PIK3CA PTEN
47
Development A2A receptor signaling 22
Show member pathways
 12.06 BRAF HRAS MAP2K2 PIK3CA
48
MAPK Pathway 72
Show member pathways
 12.05 BRAF MAP2K2 PIK3CA TP53
49
Development IGF-1 receptor signaling 22
Show member pathways
 12.03 HRAS MAP2K2 PIK3CA PTEN TP53
50
Thyroid hormone signaling pathway 37
12.02 HRAS MAP2K2 PIK3CA TP53
Sources

GO Terms for Squamous Cell Carcinoma, Head and Neck

About this section

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 BRAF FGFR3 MIR21 PTEN TP53
2 MAPK cascade GO:0000165 9.73 BRAF FGFR3 HRAS MAP2K2
3 positive regulation of gene expression GO:0010628 9.65 BRAF HRAS MIR21 PTEN TP53
4 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.54 MIR21 PTEN SMAD4
5 negative regulation of cardiac muscle hypertrophy GO:0010614 9.46 MIR21 SMAD4
6 positive regulation of metalloendopeptidase activity GO:1904685 9.4 MIR205 MIR21
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.35 BRAF FGFR3 HRAS MIR21 PTEN
8 regulation of axon regeneration GO:0048679 9.32 BRAF PTEN
9 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.16 MIR21 MIR210
10 negative regulation of cell proliferation GO:0008285 9.1 HRAS ING1 MIR21 PTEN SMAD4 TP53
Sources

Sources for Squamous Cell Carcinoma, Head and Neck

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....